Effect of food intake on the pharmacokinetics of sarpogrelate and its active metabolite following oral administration to beagle dogs

Abstract 1. The objectives of this study were to develop a pharmacokinetic model for sarpogrelate and its metabolite M-1 and to identify the effect of food on sarpogrelate and M-1 pharmacokinetics in beagle dogs. 2. A single 100 mg oral dose of sarpogrelate was administered to fasted and fed beagle dogs and the plasma concentrations of sarpogrelate and M-1 were measured simultaneously by liquid chromatography tandem mass spectrometry. The resultant data were analyzed by modeling approaches using ADAPT5. 3. The plasma concentration time course of sarpogrelate and M-1 were described using a parent-metabolite compartment model with first-order absorption and elimination. The systemic exposure of sarpogrelate and its metabolite after the administration of a single 100 mg oral dose was significantly decreased under the fed condition compared to that under the fasting condition. Modeling approaches have sufficiently explained the food effect of sarpogrelate, i.e. an increased Vc and decreased Ka, in fed dogs. The food effect of sarpogrelate was due to its pH-dependent dissolution. 4. These findings suggest that food intake affects both the rate and extent of absorption of sarpogrelate, and that the pharmacological effect of sarpogrelate can differ significantly according to food intake.

[1]  Guoqing Li,et al.  Validated LC-MS/MS method for the determination of sarpogrelate in human plasma: application to a pharmacokinetic and bioequivalence study in Chinese volunteers. , 2010, Journal of pharmaceutical and biomedical analysis.

[2]  R. Nirogi,et al.  Liquid chromatography tandem mass spectrometry method for the quantification of sarpogrelate, a selective 5-HT(₂A) receptor antagonist, in plasma: application to a pre-clinical pharmacokinetic study. , 2010, Biomedical chromatography : BMC.

[3]  Philimon N. Gona,et al.  Pharmacological modeling and biostatistical analysis of a new drug , 2010 .

[4]  T. Hanawa,et al.  Development of sarpogrelate external preparation for intractable pain control. I. Pre-formulation study on application of modified beta-cyclodextrins. , 2010, Chemical & pharmaceutical bulletin.

[5]  K. Kwon,et al.  LC-MS/MS Assay Validation for a New Immune Modulator, JHL45, and its Major Metabolite in Plasma: Application to Pharmacokinetic Studies in Rats , 2009 .

[6]  A. Terashi,et al.  Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A Randomized, Double-Blind, Aspirin-Controlled Trial , 2008, Stroke.

[7]  Kimberley A. Lentz,et al.  Current Methods for Predicting Human Food Effect , 2008, The AAPS Journal.

[8]  P. Marathe,et al.  Development and validation of a preclinical food effect model. , 2007, Journal of pharmaceutical sciences.

[9]  N. Dhalla,et al.  Therapeutic potentials of sarpogrelate in cardiovascular disease. , 2006, Cardiovascular drug reviews.

[10]  M. Rashid,et al.  Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. , 2004, Pharmacology & therapeutics.

[11]  Philippe Manivet,et al.  Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling. , 2003, Life sciences.

[12]  H. Pertz,et al.  In‐vitro Pharmacology of Sarpogrelate and the Enantiomers of its Major Metabolite: 5‐HT2A Receptor Specificity, Stereoselectivity and Modulation of Ritanserin‐induced Depression of 5‐HT Contractions in Rat Tail Artery , 1995, The Journal of pharmacy and pharmacology.

[13]  Y. Tamao,et al.  Antithrombotic Effect of MCI-9042, a New Antiplatelet Agent on Experimental Thrombosis Models , 1991, Thrombosis and Haemostasis.

[14]  R. Kikumoto,et al.  MCI–9042, a New Antiplatelet Agent Is a Selective S2-Serotonergic Receptor Antagonist , 1991, Thrombosis and Haemostasis.